Reduced incidence of hypertension after heterotopic cardiac transplantation compared with orthotopic cardiac transplantation Evidence that excision of the native heart contributes to post-transplant hypertension by Taegtmeyer, Anne B. et al.
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educed Incidence of Hypertension
fter Heterotopic Cardiac Transplantation
ompared With Orthotopic Cardiac Transplantation
vidence That Excision of the Native Heart
ontributes to Post-Transplant Hypertension
nne B. Taegtmeyer, BMBCH,*† Angela M. Crook, MSC,‡ Paul J. R. Barton, PHD,†
icholas R. Banner, FRCP*
arefield and London, United Kingdom
OBJECTIVES This study was designed to test the hypothesis that heterotopic heart transplant (HHT)
patients have lower blood pressure than orthotopic cardiac transplant (OCT) patients because
their native heart is involved in blood pressure homeostasis.
BACKGROUND Hypertension occurs more frequently after OCT than after liver or lung transplantation,
suggesting that transplantation of the heart itself contributes to post-transplant hypertension.
METHODS Blood pressure and related measurements in 233 OCT and 38 HHT patients were studied
retrospectively post-transplant.
RESULTS Systolic blood pressure (SBP) was persistently lower among HHT patients (means 121 vs.
137, 126 vs. 137, 125 vs. 139, and 128 vs. 143 mm Hg at month 3 and years 1, 3, and 5
respectively, p  0.005). Left ventricular and aortic systolic pressures were also lower (130 vs.
143 mm Hg, p  0.01 and 129 vs. 142 mm Hg, p  0.01). Multivariable analysis with age,
gender, body mass index, creatinine, steroids, cyclosporine, use of antihypertensive medica-
tion, donor left ventricular ejection fraction, donor weight, and type of transplant as
covariables showed HHT to be independently associated with a lower SBP at each time point
(beta-coefficients 16.2, 12.1, 13.3, and 14.2 mm Hg, p  0.01). The adjusted hazard
ratio for the development of systolic hypertension among HHT compared with OCT patients
was 0.59 (95% confidence interval 0.39 to 0.91, p  0.017).
CONCLUSIONS Heterotopic heart transplant patients had lower SBP than OCT patients, consistent with the
hypothesis that the native heart continues to contribute to blood pressure
homeostasis. (J Am Coll Cardiol 2004;44:1254–60) © 2004 by the American College of
Cardiology Foundationr
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aypertension develops early after cardiac transplantation
nd can be difficult to manage (1,2). Cyclosporine contrib-
tes to post-transplant hypertension through activation of
he sympathetic nervous system (3), nephrotoxicity (4), and
nhibition of endothelium-dependent vasodilation (5).
owever, other factors such as cardiac innervation may play
role, because the incidence of hypertension in liver (45%)
nd lung (66%) transplant patients receiving cyclosporine is
ower than in heart transplant patients (95% at 5 years)
1,6,7).
Evidence for the role of cardiac innervation in cardiovas-
ular homeostasis comes from human and animal studies.
utotransplantation in dogs results in increased plasma
olume (8), and human heart transplant recipients have
lunted responses to salt or volume loading (9). They also
From the *Transplant Unit, Harefield Hospital, Harefield, United Kingdom;
Heart Science Centre, Harefield Hospital, Harefield, United Kingdom; and ‡De-
artment of Public Health Research, Westminster Primary Care Trust, London,
nited Kingdom. This study was supported by the Harefield Research Foundation
nd the Royal Brompton and Harefield NHS Trust.
Manuscript received March 23, 2004; revised manuscript received May 28, 2004,iccepted June 7, 2004.espond to central blood volume reduction with an attenu-
ted increase in sympathetic activity (10).
Two types of heart transplantation are performed. The
rthotopic cardiac transplant (OCT), in which the recipi-
nt’s heart is removed and replaced by a denervated donor
eart, is the commonest. An alternative is the heterotopic
eart transplant (HHT), in which the recipient heart and its
nnervation remain intact and the donor heart is placed in
he right hemithorax with the donor and recipient left
entricles functioning in parallel (11). Heterotopic heart
ransplant is often performed when the donor organ is
maller than the recipient heart or when pulmonary artery
ressures are elevated (12).
We hypothesized that because HHT leaves the native
eart intact, its use may be associated with less hypertension
han is OCT.
ETHODS
atients. Clinical records and echocardiograms of 271
dult cardiac transplant patients transplanted at our
nstitution between 1991 and 1999 who survived longer
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September 15, 2004:1254–60 Hypertension After Cardiac Transplantationhan three months were examined. Of these, 233 had
ndergone OCT and 38 HHT. The ethics committee
ave approval.
The OCT and HHT groups were well matched in terms
f age, gender, size, indication for transplantation, pre-
ransplant blood pressure, use of angiotensin-converting
nzyme inhibitors, previous history of hypertension, and
re-transplant renal function calculated according to Cock-
roft and Gualt (13) (Table 1). As expected, donor weight
as lower in HHT than in OCT patients (mean 36 vs. 64
g, p  0.0001). Of the 38 HHT patients, 23 underwent
HT because of donor-recipient size mismatching and 15
ecause of elevated systolic pulmonary artery pressures. The
atter patients’ pre-transplant systolic blood pressures did
ot differ significantly from those of patients who received
HT on the basis of size mismatch alone (109  19 mm
g vs. 107  12 mm Hg).
Abbreviations and Acronyms
CI  cardiac index
HHT  heterotopic heart transplant
OCT  orthotopic cardiac transplant
SBP  systolic blood pressure
able 1. Pretransplant Characteristics for OCT and HHT
atients
OCT
(n  233)
HHT
(n  38)
p
Value
en 200 (86%) 29 (76%) 0.133*
omen 33 (14%) 9 (24%)
ean age (yrs) 47.6 10.6 48.2  9.9 0.76†
ge range (yrs) 18–70 23–65
thnicity
Caucasian 208 (89%) 35 (92%) 0.61‡
Asian 16 (7%) 3 (8%)
Other 9 (4%) 0 (0%)
retransplant diagnosis
Ischemic heart disease 123 (53%) 21 (55%) 0.52‡
Dilated cardiomyopathy 63 (27%) 12 (32%)
Congenital heart disease 13 (6%) 0 (0%)
Viral myocarditis 12 (5%) 3 (8%)
Other 22 (9%) 2 (5%)
ystolic blood pressure
(mm Hg)
109  17 108  18 0.81†
iastolic blood pressure
(mm Hg)
70  11 69  11 0.45†
istory of previous
hypertension
24/225§ (11%) 6/37§ (16%) 0.48*
umber of patients
receiving angiotensin-
converting enzyme
inhibitor
183/224§ (82%) 32/36§ (89%) 0.35*
erum creatinine (mol/l) 112 27 107  22 0.21†
stimated creatinine
clearance
78  22 84  27 0.15†
ody mass index (kg/m2) 24.8  4.2 25.8  3.25 0.17†
alues are n (%) or mean  SD. *Chi-square test. †Student t test. ‡Fisher exact test.
Number/number for which data available. Estimated creatinine clearance calculated
ccording to Cockroft and Gault (13).
HHT  heterotopic heart transplantation; OCT  orthotopic cardiac transplan-
mation.All patients received triple-therapy immunosuppression
cyclosporine, azathioprine, and corticosteroids). Patients
nable to tolerate cyclosporine, or patients with several early
ejection episodes, were converted to tacrolimus. When
ossible, steroids were reduced and eventually withdrawn
rom three months after transplant. Antihypertensive agents
ere angiotensin-converting enzyme inhibitors, doxazosin,
alcium channel blockers, diuretics and, rarely, beta-
lockers. Both OCT and HHT patients were treated if their
lood pressure was persistently 140/90 mm Hg (14).
Data were available for 253, 209, and 126 patients at
ears 1, 3, and 5 respectively, owing to death or follow-up
1, 3, or 5 years. Figure 1 shows survival beyond three
onths. Survival after HHT was slightly worse than after
CT, related in part to donor-recipient size mismatch
12).
easurements. Noninvasive blood pressure was mea-
ured with an oscillometric technique using the Data-
cope Accutorr Plus (Montvale, New Jersey), recom-
ended by the European Society of Hypertension (15).
eadings 140 mm Hg were measured again for confir-
ation. Native aortic valve opening in HHT patients was
igure 2. Systolic blood pressure in orthotopic cardiac transplantation
OCT) and heterotopic heart transplantation (HHT) patients three
igure 1. Survival beyond three months and up until five years in
rthotopic cardiac transplantation (OCT) and heterotopic heart transplan-
ation (HHT) patients studied; log-rank test p  0.044.onths post-transplantation. Figures and lines are means  SD.
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Hypertension After Cardiac Transplantation September 15, 2004:1254–60Table 2. Blood Pressure and Other Posttransplant Characteristics in OCT and HHT Patients
Variable OCT HHT p Value
Systolic blood pressure (mm Hg)
Month 3 137  19 (233) 121  14 (38) 0.00001*
Year 1 137  15 (217) 126  15 (36) 0.00001
Year 3 139  19 (179) 125  11 (30) 0.0002
Year 5 143  20 (102) 128  17 (24) 0.001
Diastolic blood pressure (mm Hg)
Month 3 88  13 (233) 86  14 (38) 0.3*
Year 1 89  11 (217) 85  11 (36) 0.041
Year 3 90  11 (179) 88  8 (30) 0.28
Year 5 91  11 (102) 88  14 (24) 0.26
Antihypertensive agents per patient
Month 3 0.89  0.75 (232) 0.62  0.68 (37) 0.04*
Year 1 1.1  0.9 (215) 0.7  0.6 (35) 0.009
Year 3 1.2  1.0 (177) 1  0.93 (30) 0.48
Year 5 1.2  0.89 (102) 1.1  0.76 (23) 0.8
Percentage on 1 or more antihypertensive agent
Month 3 19 (43) 11 (4) 0.35†
Year 1 72 (155) 60 (21) 0.15
Year 3 72 (128) 67 (20) 0.5
Year 5 75 (77) 78 (18) 0.78
Donor heart ejection fraction (%)
Month 3 72  7 (216) 70  17 (35) 0.16*
Year 1 73  6 (208) 71  14 (33) 0.18
Year 3 73  7 (170) 72  8 (27) 0.69
Year 5 73  6 (96) 72  8 (22) 0.66
Percentage receiving steroids
Month 3 73 (168) 59 (22) 0.08†
Year 1 45 (97) 50 (17) 0.36
Year 3 20 (35) 17 (5) 0.7
Year 5 14 (14) 22 (5) 0.33
Percentage receiving cyclosporine
Month 3 89 (207) 95 (36) 0.29†
Year 1 82 (177) 91 (32) 0.22
Year 3 81 (142) 80 (24) 0.9
Year 5 83 (85) 96 (22) 0.36
Daily cyclosporine dose (mg/kg)
Month 3 4.8  1.9 (172) 4.6  1.6 (33) 0.59*
Year 1 3.8  1.3 (171) 4.0  2 (30) 0.49
Year 3 3.0  0.9 (131) 3.0  1 (23) 0.9
Year 5 2.8  1 (78) 2.6  1 (21) 0.32
12-h post dose cyclosporine level (ng/ml)
Month 3 300  120 (207) 317  119 (36) 0.43*
Year 1 202  79 (177) 227  83 (32) 0.1
Year 3 154  43 (142) 175  71 (24) 0.05
Year 5 150  45 (171) 163  59 (27) 0.2
Percentage receiving tacrolimus
Month 3 11 (25) 5 (2) 0.3†
Year 1 18 (39) 9 (9) 0.17
Year 3 19 (34) 13 (4) 0.9
Year 5 16 (16) 4 (1) 0.17
Rejection episodes per patient 1.53  1.64 (232) 2.13  2.04 (38) 0.046*
Mean number of treatments with high-dose
methylprednisolone per patient
1.94  1.7 (232) 2.68  2.24 (38) 0.012*
Mean number of augmented immunosuppression
treatments per patient
2.33  2.24 (232) 3.13  2.8 (38) 0.052*
Median number of augmented
immunosuppression treatments per patient
2.5 (232) 2 (38)
Serum creatinine (mol/l)
Month 3 143  48 (230) 136  35.4 (38) 0.4*
Year 1 154  44 (217) 144  27 (36) 0.18
Year 3 161  64 (174) 152  30 (30) 0.42
Year 5 158  70 (98) 194  185 (22) 0.13
Continued on next page
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September 15, 2004:1254–60 Hypertension After Cardiac Transplantationssessed by echocardiography. Hemodynamic data mea-
ured at cardiac catheterization were available for 46
CT and 24 HHT cases. Acute rejection was diagnosed
istologically and graded according to International So-
iety of Heart and Lung Transplantation criteria (16).
ejection episodes were treated with augmented immu-
osuppression (three daily doses of 1 g methylpred-
isolone). Rabbit antithymocyte globulin and/or OKT3
ere also used in cases of rejection associated with
emodynamic compromise.
tatistical methods. For univariate analyses, two-tailed
tudent t test was employed to test for differences
etween means and Pearson’s chi-square or Fisher exact
est (if expected frequencies were five or less) to deter-
ine differences in proportions. Paired t tests were
mployed for analysis of matched data.
Multivariable regression models were constructed with
BP as the dependent variable using a stepwise back-
ards method. Results were expressed as beta-coefficients
nd a p value of 0.05 was considered significant.
Survival analysis was performed using life tables and
aplan-Meier methods and the log-rank test was used to
etermine significance. The development of hypertension
SBP 140 mm Hg or treatment with antihypertensive
gent[s]) over time was also examined using the Kaplan-
eier technique (17); Cox method was used to generate a
azard ratio (18). Analyses were performed using STATA 7
Stata Corp., College Station, Texas).
ESULTS
ystolic blood pressure was lower in HHT than in OCT
atients at all time points (Fig. 2, Table 2). When
orrected for multiple testing (Bonferroni correction), all
values remained 0.05. Other than at one year,
iastolic blood pressure did not differ between the two
roups. Invasively measured left ventricular and aortic
ystolic blood pressures were also lower in HHT patients
Table 3).
Heterotopic heart transplant patients required fewer
ntihypertensive agents than OCT patients, particularly
Table 2 Continued
Variable
Measured creatinine clearance adjusted for body
surface area (ml/min)
Year 1
Year 3
Year 5
Body mass index (kg/m2)
Month 3
Year 1
Year 3
Year 5
Values are mean  SD (number per group) or percentages
Abbreviations as in Table 1.t month 3 and year 1. Thus, the higher SBPs seen in jCT patients were in spite of greater use of antihyper-
ensive agents.
Use of tacrolimus (associated with less hypertension
han cyclosporin) (19) was similar between the two
roups. Acute rejection and treatment with augmented
mmunosuppression occurred more frequently among
HT patients (mean number of rejection episodes
reater than grade 1B 2.13 vs. 1.53, p  0.05) (Table 2).
eterotopic heart transplant patients also received high-
ose steroids more often than did OCT patients (mean
umber of treatments 2.68 vs. 1.94, p  0.012) (Table 2).
In keeping with heterotopic grafts and their stroke
olumes being smaller than orthotopic grafts, cardiac
ndex (CI) was significantly lower among HHT com-
ared with OCT patients (Table 3). Because a limited
umber of CI measurements were available (28 OCT and
2 HHT at year 1 or 3), CI was not included in the
ultivariable analysis. Subjects for whom CI data were
vailable were also analyzed separately: CI and SBP were
oth lower among HHT patients, even when age,
ender, and year after transplantation were matched
etween HHT and OCT subjects (mean CI 2.02  0.38
/m/m2 vs. 2.97  0.5 l/m/m2 [paired t test p  0.006],
ean SBP 124  13 mm Hg vs. 142  16 mm Hg
paired t test p  0.002]). After matching HHT and
CT patients on the basis of CI, SBP was still lower in
HT patients than in OCT patients: mean SBP 127 
3 mm Hg vs. 143  20 mm Hg (p  0.02) in 13 HHT
nd 13 OCT patients matched for CI (mean CI 2.22 
.31 and 2.2  0.32), indicating that the lower SBP seen
mong HHT patients was not due to lower CI. Sub-
roups of HHT patients were examined at year 1 and
esults are shown in Table 4.
Adjusted beta coefficients for the effect of HHT
ompared to OCT on SBP are shown in Table 5 and did
ot differ greatly from unadjusted values. In patients
eceiving cyclosporine, 12 h post-dose cyclosporine levels
id not significantly affect SBP (data not shown).
The proportion of patients with systolic hypertension
as always less in HHT than OCT patients (Fig. 3). The
azard ratio for the development of hypertension (ad-
OCT HHT p Value
4  22 (170) 54  14 (19) 0.96*
6  19 (135) 60  28 (23) 0.46
6  20 (76) 53  21 (20) 0.64
2  3.9 (194) 25.6  3.6 (33) 0.58*
7  4.4 (208) 26.9  4.1 (31) 0.95
6  4.5 (164) 27.5  4.6 (28) 0.96
0  4.7 (94) 28.1  5.3 (21) 0.93
tudent t test. †Chi-square test.5
5
5
25.
26.
27.
28.
(n). *Susted for age, gender, and body mass index using the
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Hypertension After Cardiac Transplantation September 15, 2004:1254–60ox method) in HHT compared with OCT patients was
.59 (95% confidence interval 0.39 to 0.91, p  0.017).
Figure 4 shows SBP in two patients who underwent
HT followed some months later by OCT in the native
eart position. The findings are discussed later.
ISCUSSION
he greater incidence of hypertension among OCT recip-
ents may be due to the loss of cardiac inputs to blood
ressure homeostasis. In keeping with this hypothesis, we
ound SBP to be lower in HHT patients (whose native
earts remain in situ) than in OCT patients until five years
fter transplant.
Possible mechanisms by which the native heart contrib-
tes to blood pressure homeostasis are through cardiopul-
onary baroreceptors and the release of natriuretic peptides.
ardiopulmonary baroreceptors are located within the myo-
ardium and provide tonic inhibition of sympathetic outflow
o the heart and peripheral circulation, and lower blood
ressure when filling volumes are adequate (20). When this
onic inhibitory input is disrupted, baroreflexes are impaired
10). Natriuretic peptides are released in response to myo-
ardial stretch or when the myocardium has undergone
emodeling and actions include natriuresis, diuresis, and
asodilation (21). Both atrial natriuretic peptide and brain-
ype natriuretic peptide concentrations are elevated after
CT (22). As HHT patients possess two hearts, they may
ave higher natriuretic peptide levels.
Vascular pathology could predispose to the development
f post-transplant hypertension; however, when post-
ransplant blood pressures in patients with pre-transplant
schemic heart disease was compared with blood pressure in
atients of other pre-transplant diagnoses, there was no
ifference (data not shown).
Arterial blood pressure in a HHT recipient could be
nfluenced by the parallel function of the donor and native
eft ventricles. In practice, however, the native left ventricle
able 3. Left Ventricular Pressures, Aortic Pressures, and
ardiac Index Values in 24 HHT and 43 OCT Patients
OCT
HHT
(Donor Heart)
p
Value
eft ventricular systolic
pressure (mm Hg)
143  20 (40) 130  18 (24) 0.01
eft ventricular
diastolic pressure
(mm Hg)
12  5 (41) 13  6 (23) 0.4
ystolic aortic pressure
(mm Hg)
142  20 (43) 129  17 (23) 0.01
iastolic aortic pressure
(mm Hg)
85  12 (43) 88  9 (23) 0.26
O (l/min) 5.17  1.2 (31) 4.1  0.8 (12) 0.006
I (l/min/m2) 2.6  0.6 (28) 2.22  0.4 (12) 0.05
ears post transplant 1.13 0.5 1.17  0.6 0.8
alues are mean  SD (total number for whom data available), p values refer to
tudent t test results.
CI  cardiac index; CO  cardiac output. Other abbreviations as in Table 1.f patients who have undergone HHT usually does not eontribute significantly to cardiac output, and the native
ortic valve often does not open at all (23). Subgroup
nalysis of HHT patients to determine whether aortic valve
pening might have contributed to the lower SBP showed
here was no difference in SBP between those whose aortic
alve opened and those whose valve did not. Similarly,
aced linkage (24) did not cause any difference in SBP.
hese observations support the view that the lower blood
ressure observed in the heterotopic group was not due to
HT itself, but was related to the presence of the native
eart.
Diastolic blood pressure did not differ significantly be-
ween the two groups. This could result from the physiology
f HHT where asynchronous beating of donor and recipient
earts prevents blood pressure from returning to minimum
fter donor diastole because recipient systole has already
ommenced.
The heterotopic transplant patients as a whole experi-
nced more rejection episodes requiring treatment with
ugmented immunosuppression than the OCT group. This
ay be due to the fact that more HHT patients had been
eaned from maintenance steroids by three months after
ransplantation (41% of HHT patients vs. 27% of OCT
atients) (Table 2).
Analysis of hemodynamic data for a subgroup of patients
emonstrated that CI was lower in the heterotopic patients,
robably owing to the smaller size of the donor heart and a
reater incidence of rejection in the HHT group. However,
comparison of HHT and OCT patients matched for CI
till demonstrated the difference in SBP.
In two cases, we had the opportunity to examine blood
ressure after HHT and then after OCT in the same
atient. As the heterotopic organ remained in situ after
CT, this resulted in two denervated hearts. Immunosup-
ression was with cyclosporine throughout and both pa-
ients experienced a rise in SBP after OCT (Fig. 4).
The retrospective nature of the study means that com-
lete hemodynamic data were not available for all patients
nd natriuretic peptide levels were not measured. Differ-
able 4. SBP in Different Subgroups of Heterotopic
ransplant Patients
Total
Number
Mean SBP
(mm Hg)
p
Value
ace linked 16 124  15 0.62
ot pace linked 20 127  15
ative aortic valve closed 18 125  16 0.66
ative aortic valve open 12 122  15
ative left ventricular
ejection fraction 20%
13 129  16 0.33
ative left ventricular
ejection fraction 20%
14 124  13
BP values are mean  SD and p values refer to Student t test results. By sensing the
onor right ventricle and pacing the native right atrium after a timed delay adjusted
o that recipient systole coincides with donor diastole, paced linkage causes the two
earts to contract out of phase (24).
SBP  systolic blood pressure.nces in donor-recipient size mismatching between the
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September 15, 2004:1254–60 Hypertension After Cardiac TransplantationCT and HHT groups mean they were not directly
omparable; however, donor weight was included in the
ultivariable model. Although treated blood pressure was
tudied, the difference in SBP was consistent at all time
oints and the number of antihypertensive agents used was
ncluded in the multivariable model. Also, the higher SBP
een in OCT patients was despite greater treatment with
ntihypertensive agents.
Further studies are required to determine the exact
echanism by which the native heart acts to reduce blood
ressure in the HHT group.
onclusions. Heterotopic heart transplant patients had
ower SBP, measured both invasively and noninvasively
han OCT patients, managed with the same immunosup-
ression protocol in the same center. Multivariable analysis
onfirmed that HHT was independently associated with
ower SBP compared to OCT. This is consistent with the
ypothesis that the native heart continues to play a role in
igure 3. Proportion of orthotopic cardiac transplantation (OCT) and
eterotopic heart transplantation (HHT) patients with systolic blood
ressure (SBP) 140 mm Hg (or receiving antihypertensive treatment)
able 5. Unadjusted and Backward Stepwise Multiple Regression
Model Month 3
nadjusted
HHT 16 (3.2), 0.0001 1
ackward stepwise
HHT 16.2 (2.4), 0.0001 1
Body mass index (kg/m2) 0.74 (0.32), 0.02 0.5
Steroids (yes or no) 7
Age (yrs) 0
Male gender
ariables were: type of transplant, age, gender, body mass index, steroids, serum crea
ntihypertensive agents Blank cells correspond to variables that were not significant a
f explanatory variables were not. Results remained unchanged after repeating the ana
he untransformed data are presented.
Abbreviations as in Table 1.ver time, p  0.001. Figures are numbers at risk (number of events). tlood pressure homeostasis after HHT and that its removal
n OCT contributes to the development of post transplant
ypertension.
igure 4. Systolic blood pressure in two patients who underwent hetero-
opic heart transplantation (HHT) followed by orthotopic cardiac trans-
lantation (OCT). (A) 32-year-old man; (B) 45-year-old man. * Introduc-
dels
Beta Coefficient (SE), p Value
ear 1 Year 3 Year 5
.7), 0.0001 14.0 (3.7), 0.0001 15 (4.5), 0.001
.1), 0.0001 13.3 (3.9), 0.001 14.2 (5), 0.006
22), 0.016 0.64 (0.3), 0.032
.9), 0.0001
.1), 0.046 0.5 (0.2), 0.008
12.8 (5.2), 0.016
, cyclosporine, donor left ventricular ejection fraction, donor weight, and number of
fic time points. Although systolic blood pressure was normally distributed, a number
n data that had been appropriately transformed. To ease interpretation, results usingMo
Y
1.6 (2
2.1 (3
4 (0.
.13 (1
.18 (0
tinine
t speci
lysis oion of antihypertensive agents.
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